HCA
KRTX

Harbor Capital Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Harbor Capital Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-173
Closed -$31.4K – 664
2023
Q1 		$31.4K Sell
173
-537
-76% -$103K 0.01% 246
2022
Q4 		$140K Buy
+710
New +$152K 0.14% 81

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbor Capital Advisors's KRTX Position: Q2 2023 in Review

Harbor Capital Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 173 shares — an estimated $31.4K sold.

Harbor Capital Advisors first reported a position in KRTX in Q4 2022 and held it in 2 quarters. The position peaked at $140K in Q4 2022. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Harbor Capital Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Harbor Capital Advisors sold 173 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $31.4K.
  • Harbor Capital Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Harbor Capital Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $140K in Q4 2022.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Harbor Capital Advisors's 13F filing for Q2 2023, filed 11 Jul 2023.